Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 22 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		A Dose-Finding and Double Blinded Study of JNS020 QD(Fentanyl) in Patients With Cancerous Pain Previously Untreated With Opioid Analgesics

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Supportive care				Closed				20 and over				Pharmaceutical / Industry				CR014899 JNS020QD-JPN-C02, FENPAI2003, NCT00644787

Last Modified: 12/1/1991


2.		Phase III Study of Transdermally Delivered Fentanyl vs Placebo for Pain Management in Cancer Patients (Summary Last Modified 12/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and older				NCI				NCCTG-889252 MAYO-889252, NCI-P91-0015


3.		Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 to 80				Pharmaceutical / Industry				C25608/3039/BP/US NCT00105287


4.		OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 to 80				Pharmaceutical / Industry				099-15 NCT00105937


5.		Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 to 75				Pharmaceutical / Industry				ZMF-301 NCT00126789


6.		Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				FEN-202 NCT00293020


7.		Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 and over				Pharmaceutical / Industry				FEN-201 NCT00293033


8.		Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Completed				18 to 80				Pharmaceutical / Industry				FT-018-IM 2005-002348-24, NCT00362583


9.		Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				Pharmaceutical / Industry				FT-019-IM 2006-002087-26, NCT00496392


10.		An Effectiveness and Safety Study of Fentanyl in Patients With Cancer Pain Changing From Opioid Analgesics

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				20 and over				Pharmaceutical / Industry				CR014896 NCT00641667

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute